EXHIBIT 99.1

ADVENTRX ANNOUNCES 2006 THIRD QUARTER FINANCIAL RESULTS

SAN DIEGO – November 9, 2006 – ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today announced financial results for the quarterly period ended September 30, 2006.

ADVENTRX reported loss from operations of $5.1 million for the third quarter of 2006, compared with loss from operations of $3.5 million for the third quarter of 2005. Operating expenses grew as expected and were primarily due to the Company’s ongoing clinical trials of CoFactorâ. Net loss, which includes gain on fair value of warrants of $498,000, was $4.6 million, or $0.06 per share, for the third quarter of 2006, compared with a net loss, which included loss on fair value of warrants of $13.0 million, of $16.5 million, or $0.26 per share, for the third quarter of 2005.

“In the third quarter we continued to make significant progress in the development of CoFactor and in the preparation of our other product candidates for clinical development,” said Evan M. Levine, ADVENTRX chief executive officer. “In September, we announced that we completed patient enrollment in our 300-patient CoFactor Phase IIb clinical trial for metastatic colorectal cancer (mCRC), for which we expect to announce data in the second half of 2007. In addition, we continue to enroll patients and initiate sites for our CoFactor Phase III pivotal clinical trial for mCRC, and are making preparations for a clinical trial in refractory breast cancer. We expect to initiate this CoFactor clinical trial in refractory breast cancer and to file an investigational new drug application for a bioequivalency clinical trial for ANX-530, vinorelbine emulsion, in the fourth quarter of 2006.”

“In the third quarter, we strengthened our clinical and management teams with several key appointments. We added James Merritt, MD, an oncologist and accomplished biopharmaceutical executive, as president and chief medical officer, and Joachim Schupp, MD, a veteran of Novartis Pharma AG, as vice president of medical affairs. We also brought on Patrick Keran as general counsel and appointed Jack Lief, chairman and chief executive officer for Arena Pharmaceuticals, and Dr. Alex Denner, a member of the board of directors of ImClone Systems Incorporated and a managing director of entities affiliated with Carl Icahn, to our board of directors. I am pleased that top-tier individuals who understand our industry appreciate the value of our pipeline and are excited to participate in and help shape our success.”

Third Quarter and First Three Quarters of 2006 Financial Review

Research and development expenses for the third quarter of 2006 were $3.2 million, versus $1.9 million for the third quarter of 2005. This increase was due primarily to increased costs of the Phase IIb and Phase III CoFactor clinical trials as patients continued to be enrolled in the trials, as well as increased preclinical costs related to drug development.

General and administrative expenses for the 2006 third quarter were $2.1 million, compared with $1.7 million for the same period in 2005. This increase is due primarily to continuing costs related to being a publicly-held company and costs of continuing operations in support of research and development efforts.

For the nine months ended September 30, 2006, net loss was $22.9 million, or ($0.32) per share, compared with a net loss of $22.6 million, or ($0.39) per share, for the same period in 2005.

For the first nine months of 2006, research and development expenses were $8.9 million, compared with $5.9 million for the first nine months of 2005. The increase for the nine months is primarily due to expenses related to CoFactor clinical trials and hiring of personnel.

General and administrative expenses for first nine months of 2006 were $5.5 million, compared with $3.9 million for the same period in 2005. The increase was due to factors discussed above as well as increased personnel costs due to new hires and stock-based compensation charges.

ADVENTRX reported cash, cash equivalents and short-term investments of approximately $17.1 million as of September 30, 2006, compared with $22.6 million as of December 31, 2005, and no long-term debt. Subsequent to September 30, the Company announced a registered direct offering of 14,545,000 shares of common stock at a price of $2.75 per share for gross proceeds of approximately $40 million.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing low development risk pharmaceuticals for cancer and infectious disease that enhance the efficacy and/or safety of existing therapies. More information can be found on ADVENTRX’s web site at www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause ADVENTRX’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. Such forward-looking statements are made based on management’s current expectations and beliefs and should not be regarded as a statement or representation by ADVENTRX that any of its plans, including its anticipated milestones, will be achieved on time or at all. The potential risks and uncertainties that could cause actual results to differ materially include, but are not limited to: the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its anticipated or stated goals and milestones; the potential to attract a strategic partner and the terms of any related transaction; the ability to timely enroll subjects in ADVENTRX’s current and anticipated clinical trials; the potential for CoFactor® and ADVENTRX’s other product candidates to receive regulatory approval for one or more indications on a timely basis or at all, and the uncertain process of seeking regulatory approval; other difficulties or delays in developing, testing, manufacturing and marketing of and obtaining regulatory approval for CoFactor® or ADVENTRX’s other product candidates; the potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings; the scope and validity of patent protection for CoFactor® and ADVENTRX’s other product candidates; and other risks and uncertainties more fully described in ADVENTRX’s press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX’s public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. All forward-looking statements are qualified in their entirety by this cautionary statement and ADVENTRX assumes no obligation to revise or update any forward-looking statement, including as set forth in this press release, to reflect events or circumstances arising after the date on which it was made.

Contact:
ADVENTRX Pharmaceuticals
Andrea Lynn
858-552-0866

[Tables to Follow]

# # #

ADVENTRX PHARMACEUTICALS, INC.
(A Development Stage Enterprise)
Condensed Consolidated Statements of Operations
(unaudited)

	Three months ended September 30,						Nine months ended September 30,
	2006			2005			2006			2005
Net sales	$	—		$	—		$	—		$	—
Cost of goods sold		—			—			—			—
Gross margin		—			—			—			—
Grant revenue		—			—			—			—
Interest income		221,271			159,373			709,912			261,292
		221,271			159,373			709,912			261,292
Operating expenses:
Research and development		3,223,554			1,870,465			8,941,147			5,893,288
General and administrative		2,055,441			1,737,052			5,545,370			3,929,546
Depreciation and amortization		49,326			34,331			127,528			96,422
In-process research and development		—			—			10,422,130			—
Impairment loss — write off of goodwill		—			—			—			—
Interest expense		—			—			—			—
Equity in loss of investee		—			—			—			—
Total operating expenses		5,328,321			3,641,848			25,036,175			9,919,256
Loss from operations		(5,107,050	)		(3,482,475	)		(24,326,263	)		(9,657,964	)
Gain (loss) on fair value of warrants		497,869			(12,972,392	)		1,434,115			(12,972,392	)
Loss before cumulative effect of change in accounting principle		(4,609,181	)		(16,454,867	)		(22,892,148	)		(22,630,356	)
Cumulative effect of change in accounting principle		—			—			—			—
Net loss		(4,609,181	)		(16,454,867	)		(22,892,148	)		(22,630,356	)
Preferred stock dividends		—			—			—			—
Net loss applicable to common stock	$	(4,609,181	)	$	(16,454,867	)	$	(22,892,148	)	$	(22,630,356	)
Net loss per common share – basic and diluted:	$	(.06	)	$	(.26	)	$	(.32	)	$	(.39	)
Weighted average shares – basic and diluted		73,435,715			63,255,407			70,895,528			57,346,039

ADVENTRX PHARMACEUTICALS, INC.
(A Development Stage Enterprise)
Condensed Consolidated Balance Sheets

	September 30,			December 31,
	2006			2005
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	16,201,019		$	14,634,618
Accrued interest income		13,384			10,214
Prepaid expenses		916,115			255,802
Short-term investments		894,489			7,958,458
Total current assets		18,025,007			22,859,092
Property and equipment, net		447,445			407,544
Other assets		301,305			355,137
Total assets	$	18,773,757		$	23,621,773
Liabilities and Shareholders’ Deficiency
Current liabilities:
Accounts payable	$	73,584		$	593,228
Accrued liabilities		1,873,091			930,274
Accrued salary and related taxes		435,911			173,398
Warrant liability		28,262,296			29,696,411
Total current liabilities		30,644,882			31,393,311
Long-term liabilities		41,019			57,078
Total liabilities		30,685,901			31,450,389
Commitments and contingencies
Temporary equity:
Common stock subject to continuing registration, $.001 par value; 10,810,809 shares issued and outstanding		—			—
Shareholders’ deficiency:
Common stock, $0.001 par value. Authorized 200,000,000 shares; issued 63,260,334 shares in 2006 and 56,529,388 shares in 2005		74,095			67,364
Additional paid-in capital		70,904,626			52,105,329
Accumulated other comprehensive income (loss)		870			(1,722	)
Deficit accumulated during the development stage		(82,856,988	)		(59,964,840	)
Treasury stock, 23,165 shares at cost		(34,747	)		(34,747	)
Total shareholders’ deficiency		(11,912,144	)		(7,828,616	)
Total liabilities and shareholders’ deficiency	$	18,773,757		$	23,621,773